↓ Skip to main content

GLP-1 based therapeutics: simultaneously combating T2DM and obesity

Overview of attention for article published in Frontiers in Neuroscience, March 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
3 X users

Citations

dimensions_citation
98 Dimensions

Readers on

mendeley
98 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
GLP-1 based therapeutics: simultaneously combating T2DM and obesity
Published in
Frontiers in Neuroscience, March 2015
DOI 10.3389/fnins.2015.00092
Pubmed ID
Authors

Kristy M. Heppner, Diego Perez-Tilve

Abstract

Glucagon-like peptide-1 (GLP-1) enhances meal-related insulin secretion, which lowers blood glucose excursions. In addition to its incretin action, GLP-1 acts on the GLP-1 receptor (GLP-1R) in the brain to suppress feeding. These combined actions of GLP-1R signaling cause improvements in glycemic control as well as weight loss in type II diabetes (T2DM) patients treated with GLP-1R agonists. This is a superior advantage of GLP-1R pharmaceuticals as many other drugs used to treat T2DM are weight neutral or actual cause weight gain. This review summarizes GLP-1R action on energy and glucose metabolism, the effectiveness of current GLP-1R agonists on weight loss in T2DM patients, as well as GLP-1R combination therapies.

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 98 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Switzerland 1 1%
Italy 1 1%
South Africa 1 1%
Spain 1 1%
United States 1 1%
Unknown 93 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 22 22%
Student > Bachelor 16 16%
Researcher 15 15%
Student > Postgraduate 6 6%
Professor > Associate Professor 6 6%
Other 18 18%
Unknown 15 15%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 18 18%
Medicine and Dentistry 16 16%
Pharmacology, Toxicology and Pharmaceutical Science 12 12%
Agricultural and Biological Sciences 12 12%
Neuroscience 8 8%
Other 13 13%
Unknown 19 19%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 March 2015.
All research outputs
#17,283,763
of 25,371,288 outputs
Outputs from Frontiers in Neuroscience
#8,065
of 11,537 outputs
Outputs of similar age
#169,075
of 277,725 outputs
Outputs of similar age from Frontiers in Neuroscience
#101
of 141 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 11,537 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.9. This one is in the 24th percentile – i.e., 24% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,725 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 141 others from the same source and published within six weeks on either side of this one. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.